Insider Trading activities of Xenon Pharmaceuticals Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xenon Pharmaceuticals Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Xenon Pharmaceuticals Inc. since year 2005. Table 2 shows the detailed insider transactions of Xenon Pharmaceuticals Inc. since 2005. The reporting company's ticker symbol is XENE. The reporting company's CIK number is 1582313.
The total value of stock buying since 2005 is $2,530,765.
The total value of stock sales since 2005 is $666,654.
The total value of stock option exercises since 2005 is $857,004.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Xenon Pharmaceuticals Inc. (XENE).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-11 15,000 $33,285 0 $0 0 $0
2017-09 10,000 $29,500 0 $0 0 $0
2017-08 198,037 $544,013 0 $0 0 $0
2017-06 490,978 $1,891,107 0 $0 1,028 $3,608
2017-05 0 $0 0 $0 2,057 $6,602
2017-03 0 $0 0 $0 60,698 $217,784
2016-12 0 $0 30,000 $235,500 39,093 $125,487
2016-08 0 $0 30,000 $234,492 0 $0
2016-07 0 $0 0 $0 12,345 $40,738
2016-06 5,300 $32,860 0 $0 0 $0
2016-05 0 $0 0 $0 8,230 $27,159
2016-04 0 $0 0 $0 1,543 $5,169
2015-12 0 $0 0 $0 2,880 $15,033
2015-11 0 $0 0 $0 10,595 $55,305
2015-09 0 $0 22,149 $196,662 30,388 $106,145
2015-08 0 $0 0 $0 28,803 $141,164
2015-06 0 $0 0 $0 1,543 $7,637
2015-02 0 $0 0 $0 5,144 $24,742
2015-01 0 $0 0 $0 16,151 $80,431

Table 2. Detailed insider stock purchases, sales, and option exercises of Xenon Pharmaceuticals Inc. insiders (XENE)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-11-15 Azab Mohammad Buy 15,000 2.22 33,285
2017-09-22 Azab Mohammad Buy 8,000 2.95 23,600
2017-09-21 Azab Mohammad Buy 2,000 2.95 5,900
2017-08-18 Winquist Raymond (Head, Translational Research) Buy 1,000 3.00 2,995
2017-08-18 Azab Mohammad Buy 6,312 2.90 18,304
2017-08-17 Azab Mohammad Buy 23 2.65 60
2017-08-15 Empfield James R. (SVP, Drug Discovery) Buy 10,000 2.48 24,820
2017-08-15 Lampert Mark N Buy 18,858 2.41 45,485
2017-08-14 Svoronos Dawn Buy 50,000 2.81 140,750
2017-08-14 Hayden Michael R Buy 15,000 2.75 41,250
2017-08-14 Lampert Mark N Buy 41,344 2.70 111,794
2017-08-11 Gannon Steven Buy 15,000 2.82 42,270
2017-08-10 Pimstone Simon N. (President & CEO) Buy 6,000 2.90 17,400
2017-08-10 Mortimer Ian (CFO & COO) Buy 15,000 2.87 43,095
2017-08-10 Patou Gary Buy 7,500 2.78 20,835
2017-08-10 Scheller Richard H Buy 7,000 2.85 19,950
2017-08-08 Patou Gary Buy 5,000 3.00 15,005
2017-06-27 Lampert Mark N Buy 85,461 4.00 341,844
2017-06-22 Lampert Mark N Buy 8,263 4.00 33,052
2017-06-21 Lampert Mark N Buy 12,148 4.00 48,592
2017-06-19 Tarnow Michael M Option Ex 1,028 3.51 3,608
2017-06-19 Lampert Mark N Buy 3,595 3.85 13,840
2017-06-16 Lampert Mark N Buy 11,034 3.85 42,480
2017-06-15 Lampert Mark N Buy 11,779 3.84 45,196
2017-06-07 Lampert Mark N Buy 207,789 3.85 800,195
2017-06-06 Lampert Mark N Buy 150,909 3.75 565,908
2017-05-12 Robin Sherrington (SVP Bus. & Corp. Development) Option Ex 2,057 3.21 6,602
2017-03-14 Hayden Michael R Option Ex 60,698 3.59 217,784
2016-12-15 Holler Frank A Sale 30,000 7.85 235,500
2016-12-12 Tarnow Michael M Option Ex 14,403 3.21 46,233
2016-12-06 Patou Gary Option Ex 12,345 3.21 39,627
2016-12-01 Azab Mohammad Option Ex 12,345 3.21 39,627
2016-08-19 Holler Frank A Sale 11,938 7.65 91,337
2016-08-18 Holler Frank A Sale 9,599 7.70 73,912
2016-08-17 Holler Frank A Sale 1,600 7.89 12,624
2016-08-16 Holler Frank A Sale 6,863 8.25 56,619
2016-07-29 Pimstone Simon N. (President & CEO) Option Ex 12,345 3.30 40,738
2016-06-24 Mortimer Ian (CFO & COO) Buy 5,300 6.20 32,860
2016-05-25 Hayden Michael R Option Ex 8,230 3.30 27,159
2016-04-28 Tarnow Michael M Option Ex 1,543 3.35 5,169
2015-12-16 Robin Sherrington (SVP Bus. & Corp. Development) Option Ex 411 5.22 2,145
2015-12-11 Azab Mohammad Option Ex 2,469 5.22 12,888
2015-11-24 Holler Frank A Option Ex 2,057 5.22 10,737
2015-11-04 Patou Gary Option Ex 3,497 5.22 18,254
2015-11-02 Tarnow Michael M Option Ex 5,041 5.22 26,314
2015-09-24 Goldberg Y. Paul (VP of Clinical Development) Sale 12,000 8.60 103,200
2015-09-23 Goldberg Y. Paul (VP of Clinical Development) Sale 4,000 9.02 36,080
2015-09-22 Goldberg Y. Paul (VP of Clinical Development) Sale 6,149 9.33 57,382
2015-09-22 Goldberg Y. Paul (VP of Clinical Development) Option Ex 30,388 3.49 106,145
2015-08-18 Pimstone Simon N. (President & CEO) Option Ex 20,576 4.89 100,719
2015-08-18 Robin Sherrington (SVP Bus. & Corp. Development) Option Ex 3,085 4.89 15,101
2015-08-18 Goldberg Y. Paul (VP of Clinical Development) Option Ex 3,085 4.89 15,101
2015-08-18 Holler Frank A Option Ex 2,057 4.98 10,243
2015-06-17 Tarnow Michael M Option Ex 1,543 4.95 7,637
2015-02-03 Hayden Michael R Option Ex 5,144 4.81 24,742
2015-01-08 Hayden Michael R Option Ex 5,144 4.98 25,617
2015-01-08 Azab Mohammad Option Ex 2,469 4.98 12,295
2015-01-08 Tarnow Michael M Option Ex 5,041 4.98 25,104
2015-01-07 Patou Gary Option Ex 3,497 4.98 17,415

Insider trading activities including stock purchases, stock sales, and option exercises of XENE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Xenon Pharmaceuticals Inc. (symbol XENE, CIK number 1582313) see the Securities and Exchange Commission (SEC) website.